![]() ![]() With our pipeline, we completed enrollment in our TEPEZZA chronic, Low-CAS TED trial, we expect to share top line results in the second quarter of next year. Our continued focus on clinical, commercial and operational execution drove progress across our portfolio this quarter. Thank you, Tina, and good morning, everyone. These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings press release, our slide presentation and other filings from today that are available on our investor website at I will now turn the call over to Tim. In addition, on today's conference call, non-GAAP financial measures will be used. You're cautioned not to place undue reliance on these forward-looking statements, and Horizon disclaims any obligation to update such statements. Our actual results could differ materially from these forward-looking statements due to a number of factors, including the risk factors and other information outlined in our latest Forms 10-K, 10-Q and any 8-Ks filed with the Securities and Exchange Commission and our earnings press release, which we issued this morning. We posted our investor slide deck this morning as well.ĭuring today's call, we'll be making certain forward-looking statements, including statements about financial projections, development activities, our business strategy and the expected timing and impact of future events. After closing remarks from Tim, we'll take your questions. Liz will then review our R&D programs, followed by Aaron, who will discuss our financial performance and guidance in more detail. Tim will provide a review of the business, including our third quarter performance and full year guidance. On the call with me today are Tim Walbert, Chairman, President and Chief Executive Officer Liz Thompson, Executive Vice President, Research and Development Aaron Cox, Executive Vice President and Chief Financial Officer and Andy Pasternak, Executive Vice President, Chief Strategy Officer. Good morning, everyone, and thank you for joining us. Tina Ventura, Senior Vice President and Chief Investor Relate Officer. ![]() ![]() As a reminder, today's conference call is being recorded. Welcome to the Horizon Therapeutics plc Third Quarter 2022 Earnings Conference Call. Good morning, and thank you for standing by. Gary Nachman - BMO Capital Markets Equity Research Liz Thompson - Executive Vice President, Research & DevelopmentĪaron Cox - Executive Vice President and Chief Financial OfficerĪndy Pasternak - Executive Vice President, Chief Strategy Officer Tim Walbert - Chairman, President and Chief Executive Officer Tina Ventura - Senior Vice President, Chief Investor Relations Officer Horizon Therapeutics Public Limited Company ( NASDAQ: HZNP) Q3 2022 Results Conference Call Novem8:00 AM ET ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |